Therefore, we hypothesized that its methylation status could be a novel predictor of therapeutic resistance and poor outcome, serving as a potential counterpoint or complement to MGMT because of its reported role in promoting cell proliferation, invasion, and resistance to apoptosis in GBM. The gene discussed is MGMT; the disease is glioblastoma.